Search

Author/Creator Chander, P.

1. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study. (December 2022)

Authors:
Girard, N.; Christoph, D.C.C.; Garassino, M.C.; McDonald, F.; Mornex, F.; Field, J.K.; Fietkau, R.; Garrido Lopez, P.; Haakensen, V.D.; Siva, S.; van den Heuvel, M.; Bar, J.; Chouaid, C.; Vercauter, P.; Chander, P.; Licour, M.; Anand, S.; de Lima, A.R.M.D.; Filippi, A.R.R.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗